AHA 2011 in Orlando: Late-Breaking Clinical Trials Reply

Late-Breaking Clinical Trials I.
Sunday, Nov 13, 2011, 3:45 PM – 5:13 PM
West Hall B4
Moderators: Jeffrey Weitz, Hamilton, ON, Canada; Gilles Montalescot, Paris, France

3:45 PM: Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention: AIDA STEMI Trial
Holger Thiele, Herzzentrum Leipzig, Leipzig, Germany; Jochen Wöhrle, Univ of Ulm, Ulm, Germany; Rainer Hambrecht, Klnikum Links der Weser, Bremen, Germany; Harald Rittger, Klnikum Coburg, Coburg, Germany; Ralf Birkemeyer, Klnikum Villingen-Schwenningen, Villingen-Schwenningen, Germany; Bernward Lauer, Zentralklinik Bad Berka, Bad Berka, Germany; Petra Neuhaus, Oana Brosteanu, KKSL, Leipzig, Germany; Peter Sick, Krankenhaus Barmherzige Brüder, Regensburg, Germany; Marcus Wiemer, HERHerz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany; Sebastian Kerber, Herz- und Gefäß-Klinik, Bad Neustadt, Germany; Ingo Eitel, Herzzentrum Leipzig, Leipzig, Germany; Klaus Kleinertz, Ambulantes Herzzentrum Chemnitz, Chemnitz, Germany; Gerhard Schuler, Herzzentrum Leipzig, Leipzig, Germany
Discussant: Alice K Jacobs, Boston, MA

4:07 PM:  Abciximab Plus Unfractionated Heparin versus Bivalirudin in Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. The ISAR-REACT 4 Randomized Trial
Adnan Kastrati, Deutsches Herzzentrum, Munich, Germany; Franz-Josef Neumann, Herz-Zentrum, Bad Krozingen, Germany; Stefanie Schulz, Steffen Massberg, Deutsches Herzzentrum, Munich, Germany; Karl-Ludwig Laugwitz, Klinikum rechts der Isar, Munich, Germany; Miroslaw Ferenc, Herz-Zentrum, Bad Krozingen, Germany; David Antoniuccu, Azienda Ospedaliero-Univria Careggi, Florence, Italy; Peter B Berger, Geisinger Medical Ctr, Danville, PA; Julinda Mehilli, Albert Schomig, Deutsches Herzzentrum, Munich, Germany
Discussant: Deepak Bhatt, Boston, MA

4:29 PM: Extended Anticoagulant Prophylaxis in Initially Hospitalized Medically Ill Patients: Results of the ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) Trial
Samuel Z Goldhaber, Brigham and Women’s Hosp, Boston, MA; Sylvia Haas, Inst for Experimental Oncology and Therapy Res, Technical Univ of Munich, Munich, Germany; Ajay Kakkar, Thrombosis Res Inst and Univ Coll London, London, United Kingdom; Robert M Knabb, Bristol-Myers Squibb, Princeton, NJ; Alain Leizorovicz, Unité de Pharmacologie Clinique, Univ Claude Bernard Lyon I, Lyon, France; Geno Merli, Jefferson Medical Coll, Thomas Jefferson Univ Hosp, Philadelphia, PA; Jeffrey Weitz, Thrombosis and Atherosclerosis Res Inst and McMaster Univ, Hamilton, ON, Canada
Discussant: Mary Cushman, Colchester, VT

4:51 PM: The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER) Trial
Kenneth W Mahaffey, Pierluigi Tricoci, Yuliya Lokhnygina, Duke Clinical Res Inst, Durham, NC; Paul W Armstrong, Univ of Alberta, Edmonton, AB, Canada; Philip Aylward, Flinders Medical Ctr, Adelaide, Australia; Edmond Chen, Merck & Co., Inc., Whitehouse Station, NJ; Claes Held, Uppsala Clinical Res Ctr, Uppsala, Sweden; Sergio Leonardi, Duke Clinical Res Inst, Durham, NC; Ann M Kilian, Merck & Co., Inc., Whitehouse Station, NJ; David J Moliterno, Univ of Kentucky, Lexington, KY; Tyrus L Rorick, Duke Clinical Res Inst, Durham, NC; John Strony, Merck & Co., Inc., Whitehouse Station, NJ; Frans Van de Werf, Univ of Leuven, Leuven, Belgium; Lars Wallentin, Uppsala Clinical Res Ctr, Uppsala, Sweden; Harvey D White, Green Lane Cardiovascular Service, Auckland, New Zealand; Robert A Harrington, Duke Clinical Res Inst, Durham, NC

5:13 PM: Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) Trial: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with Acute Coronary Syndrome
C Michael Gibson, Beth Israel Deaconess Med Ctr, Boston, MA

Late-Breaking Clinical Trials II
Monday, Nov 14, 2011, 10:45 AM -12:13 PM
West Hall B4
Moderators: Frederick A Masoudi, Aurora, CO; Clyde W Yancy, Chicago, IL

10:45 AM: The Impact of Full Coverage for Preventive Medications After Myocardial Infarction on Recurrent Vascular Events: The Post-MI Free Rx Event and Economic Evaluation (Post-MI FREEE) Trial
Niteesh K Choudhry, Jerry Avorn, Robert Glynn, Elliott M Antman, Sebastian Schneeweiss, Harvard Medical Sch, Boston, MA; Michele Toscano, Lonny Reisman, Joaquim Fernandes, Claire M Spettell, Aetna, Hartford, CT; Joy L Lee, Raisa Levin, Harvard Medical Sch, Boston, MA; Troyen Brennan, CVS Caremark, Woonsocket, RI; William H Shrank, Harvard Medical Sch, Boston, MA
 Discussant: Eric D Peterson, Durham, NC

11:07 AM: Pharmacist Intervention to Prevent Hospitalization and Death in Patients with Heart Failure: A Prospective Cluster Randomised Controlled Trial
Richard Lowrie, Natl Health Service, Greater Glasgow and Clyde, Glasgow, United Kingdom; Frances Mair, Dept of General Practice and Primary Care, Univ of Glasgow, Glasgow, United Kingdom; Nicola Greenlaw, Robertson Ctr for Biostatistics, Glasgow, United Kingdom; Paul Forsyth, Natl Health Service, Greater Glasgow and Clyde, Glasgow, United Kingdom; Alex McConnachie, The Robertson Ctr for Biostatistics, Glasgow, United Kingdom; Brian Rae, Natl Health Service, Greater Glasgow and Clyde, Glasgow, United Kingdom; John McMurray, BHF Cardiovascular Res Ctr, Glasgow, United Kingdom
Discussant: Mariell Jessup, Philadelphia, PA

11:29 AM: Testing an Evidence-Based, Individualized Informed Consent Form to Improve Patients’ Experiences with PCI
John Spertus, Eizabeth Gialde, Adnan Chhatriwalla, Kensey Gosch, Philip G Jones, John McCartan, Mid America Heart Inst, Kansas City, MO; Edward J McNulty, Kaiser Permanente – San Francisco, San Francisco, CA; Mayra Guerrero, Henry Ford Health System, Detroit, MI; Aaron Kugelmass, Baystate Medical Ctr, Springfield, MA; Richard Bach, Washington Univ, Saint Louis, MO; Jeptha Curtis, Yale Univ, New Haven, CT; Charles Bethea, Integris Healthsystem, Oklahoma City, OK; Marc Shelton, Prairie Cardiovascular Inst, Springfield, IL; Bradley Leonard, Baylor Health System – Plano, Plano, TX; Henry Ting, Mayo Clinic, Rochester, MN; Carole Decker, Mid America Heart Inst, Kansas City, MO
Discussant: Manesh Patel, Durham, NC

11:51 AM: Outcomes of Non-Primary PCI at Hospitals with and Without On-Site Cardiac Surgery: A Randomized Study
Thomas Aversano, Johns Hopkins Medical Insts, Baltimore, MD

Late-Breaking Clinical Trials III
Monday, Nov 14, 2011, 3:45 PM – 5:13 PM
Chapin Theater
Moderators: Douglas P Zipes, Carmel, IN; Alan J Camm, London, United Kingdom

3:45 PM: Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone 50, 100 Or 300 Mg OD with Amiodarone as Calibrator for the Prevention of ICD Interventions or Death (ALPHEE)
Peter R. Kowey, MLH Heart Ctr Lankenau Medical Ctr, Wynnewood, PA; Etienne M Aliot, Cardiovascular Inst Univ of Nancy, Nancy, France; Alessandro Capucci, Ospedale Torrette, Ancona, Italy; Stuart J Connolly, McMaster Univ, Hamilton, ON, Canada; Harry JGM Crijns, Univ Hosp Maastricht, Maastricht, Netherlands; Stefan H Hohnloser, J.W. Goethe Univ, Frankfurt, Germany; David Radzik, Sanofi Res and Development, Paris, France; Piotr Kulakowski, Grochowski Hosp, Warsaw, Poland; Denis Roy, Univ de Montreal, Quebec, QC, Canada

4:07 PM: Atrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: a Multi-center Randomized Clinical Trial
Lucas Boersma, St.Antonius Hosp, Nieuwegein, Netherlands; Manuel Castella, Hosp Clinic, Barcelona, Spain; WimJan Van Boven, St.Antonius Hosp, Nieuwegein, Netherlands; Antonio Berruezo, Hosp Clinic, Barcelona, Spain; Allaadin Yilmaz, Johannes Kelder, St.Antonius Hosp, Nieuwegein, Netherlands; Josep Brugada, Hosp Clinic, Barcelona, Spain; Maurits Wijffels, St.Antonius Hosp, Nieuwegein, Netherlands; Lluis Mont, Hosp Clinic, Barcelona, Spain
Discussant: A Marc Gillinov, Cleveland, OH

4:20 PM: A Randomized Multicenter Comparison of Radiofrequency Ablation and Antiarrhythmic Drug Therapy as First-Line Treatment in 294 Patients with Paroxysmal Atrial Fibrillation
Jens Cosedis Nielsen, Aarhus Univ Hosp, Skejby, Aarhus N, Denmark; Arne Johannessen, Gentofte Hosp, Hellerup, Denmark; Pekka Raatikainen, Oulu Univ Hosp, Oulu, Finland; Gerhard Hindricks, Herzzentrum Leipzig, Leipzig, Germany; Håkan Walfridsson, Linköping Univ Hosp, Linköping, Sweden; Ole Kongstad, Lund Univ Hosp, Lund, Sweden; Steen Michael Pehrson, Rigshospitalet, Copenhagen, Denmark; Anders Englund, Örebro Univ Hosp, Örebro, Sweden; Juha Hartikainen, Kuopio Univ Hosp, Kuopio, Finland; Leif Spange Mortensen, UNI-C, Aarhus N, Denmark; Peter Steen Hansen, Varde Heart Ctr, Varde, Denmark
Discussant: William G Stevenson, Boston, MA

4:51 PM: The Results of the PALLAS Study
Stuart J Connolly, Hamilton General Hosp, Hamilton, ON, Canada; Stefan H Hohnloser, JW Goethe Univ, Frankfurt, Germany
Discussant: NA Mark Estes III, Boston, MA

Late-Breaking Clinical Trials IV
Tuesday, Nov 15, 2011, 10:45 AM -12:13 PM
West Hall B4
Moderators: Donald M Lloyd-Jones, Chicago, IL; John J Kastelein, Amsterdam, Netherlands

10:45 AM: Practice-Based Opportunities for Weight Reduction (POWER)
Lawrence J Appel, Johns Hopkins Medical Insts Univ, Baltimore, MD
Discussant: Frank Sacks, Boston, MA

11:07 AM: Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results
Stephen J Nicholls, Cleveland Clinic, Cleveland, OH; Christie M Ballantyne, Baylor Coll of Med, Houston, TX; Philip J Barter, Heart Res Inst, Sydney, Australia; M John Chapman, Hôpital de la Pitié, Paris, France; Raimund M Erbel, West-German Heart Ctr, Essen, Germany; Peter Libby, Brigham and Womens Hosp, Boston, MA; Joel S Raichlen, AstraZeneca, Wilmington, DE; Marilyn Borgman, Kathy Wolski, Steven E Nissen, Cleveland Clinic, Cleveland, OH

11:29 AM: Lipid-Modulating Effects of Evacetrapib, a Novel CETP Inhibitor, Administered as Monotherapy or in Combination with the Most Commonly-Used Statins
Stephen J Nicholls, Cleveland Clinic, Cleveland, OH; Bryan Brewer, MedStar Res Inst, Washington, DC; John JP Kastelein, Academic Medical Ctr / Univ of Amsterdam, Amsterdam, Netherlands; Kathryn A Krueger, Ming-Dauh Wang, Eli Lilly, Indianapolis, IN; Kathy Wolski, Ellen McErlean, Steven E Nissen, Cleveland Clinic, Cleveland, OH
Discussant: Daniel J Rader, Philadelphia, PA

11:51 AM: Extended-Release Niacin Does Not Reduce Clinical Events in Patients with Established Cardiovascular Disease Whose LDL-Cholesterol is Optimally Controlled with Statin Therapy: Results from the AIM-HIGH Trial 
William E Boden, Univ of Buffalo, Buffalo, NY; Jeffrey L Probstfield, Univ of Washington, Seattle, WA
Discussant: Philip Barter, Sydney Nsw, Australia

Late-Breaking Clinical Trials V: Peripheral Vascular Disease
Wednesday, Nov 16, 2011, 10:45 AM -12:13 PM
West Hall B4
Moderators: Valentin Fuster, New York, NY; Patrick T O’Gara, Boston, MA

10:45 AM: Randomized Trial of Early Surgery versus Conventional Treatment for Infective Endocarditis (EASE)
Duk-Hyun Kang, Asan Medical Ctr, Seoul, Korea, Republic of; Yong-Jin Kim, Seoul Natl Univ Hosp, Seoul, Korea, Republic of; Sung-Han Kim, Byung Joo Sun, Dae-Hee Kim, Jong-Min Song, Suk Jung Choo, Kee-Joon Choi, Jae-Kwan Song, Jae-Won Lee, Asan Medical Ctr, Seoul, Korea, Republic of; Dae-Won Sohn, Seoul Natl Univ Hosp, Seoul, Korea, Republic of

11:07 AM: Claudication Treatment Comparative Effectiveness: 6 Month Outcomes From the CLEVER Study
Timothy P Murphy, Rhode Island Hosp, Providence, RI; Donald Cutlip, Beth Israel Deaconess Hosp, Boston, MA; Judith Regensteiner, Univ of Colorado Health Sciences Ctr, Denver, CO; Emile Mohler, Univ of Pennsylvania, Philadelphia, PA; Suzanne Goldberg, Natl Heart Lung and Blood Inst, Bethesda, MD; Joseph Massaro, Boston Univ, Boston, MA; David Cohen, St. Luke’s Hosp, Kansas City, MO; Matthew Reynolds, Beth Israel Deaconess Hosp, Boston, MA; Beth Lewis, Health Partners, Minneapolis, MN; Joselyn Cerezo, Rhode Island Hosp, Providence, RI; Niki Oldenburg, Univ of Minnesota, Minneapolis, MN; Claudia Thum, Harvard Clinical Res Inst, Boston, MA; Alan Hirsch, Univ of Minnesota, Minneapolis, MN
Discussant: Michael S Conte, San Francisco, CA

11:29 AM: Colchicine Reduces Post-Operative Atrial Fibrillation. Results of the COPPS Atrial Fibrillation Study
Massimo Imazio, Maria Vittoria Hosp, Torino, Italy; Antonio Brucato, Paolo Ferrazzi, Ospedali Riuniti, Bergamo, Italy; Maria Elena Rovere, Ospedale Mauriziano, Torino, Italy; Anna Gandino, Ospedale Niguarda, Milano, Italy; Roberto Cemin, San Maurizio Regional Hosp, Bolzano, Italy; Stefania Ferrua, Cardiology, Ospedale degli Infermi, Rivoli, Italy; Riccardo Belli, Rita Trinchero, Maria Vittoria Hosp, Torino, Italy; David H Spodick, St. Vincent Hosp, Univ of Massachusetts, Worcester, MA; Yehuda Adler, Sackler Faculty of Med, Tel-Aviv and Misgav ladach Hosp, Jerusalem, Kupat Holim Meuhedet, Jerusalem, Israel
Discussant: Nancy Nussmeier, Syracuse, NY

11:51 AM: ELEVATE-TIMI 56: Escalating Clopidogrel by Involving a Genetic Strategy-TIMI 56
Jessica L Mega, Brigham and Women’s Hosp, Boston, MA; Willibald Hochholzer, Herz-Zentrum Bad Krozigen, Bad Krozingen, Germany; Andrew L Frelinger III, Children’s Hosp Boston, Boston, MA; Michael J Kluk, Brigham and Women’s Hosp, Boston, MA; Steven Isserman, Clinical Trials of America, Hickory, NC; William J Rogers, Univ of Alabama at Birmingham Medical Ctr, Birmingham, AL; Dominick J Angiolillo, Univ of Florida Coll of Med, Jacksonville, FL; Dean J Kereiakes, The Christ Hosp Heart & Vascular Ctr / The Lindner Res Ctr, Cincinnati, OH; Christian T Ruff, David D Berg, John Cyr, Benjamin M Scirica, Laura Grip, Robert A Mesa, John F Mattimore, Janina A Longtine, Brigham and Women’s Hosp, Boston, MA; Alan D Michelson, Children’s Hosp Boston, Boston, MA; Marc S Sabatine, Brigham and Women’s Hosp, Boston, MA

What do you think?

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s